Compare FLGT & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLGT | ORGO |
|---|---|---|
| Founded | 2011 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.3M | 624.4M |
| IPO Year | 2016 | N/A |
| Metric | FLGT | ORGO |
|---|---|---|
| Price | $27.16 | $4.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $28.33 | $8.00 |
| AVG Volume (30 Days) | 272.3K | ★ 1.5M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $315,549,000.00 | ★ $465,218,000.00 |
| Revenue This Year | $16.84 | $8.14 |
| Revenue Next Year | $9.74 | $6.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.61 | 2.24 |
| 52 Week Low | $14.57 | $2.61 |
| 52 Week High | $31.04 | $7.08 |
| Indicator | FLGT | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 47.00 | 46.12 |
| Support Level | $26.69 | $4.61 |
| Resistance Level | $31.04 | $5.83 |
| Average True Range (ATR) | 0.77 | 0.22 |
| MACD | -0.46 | -0.08 |
| Stochastic Oscillator | 10.80 | 21.05 |
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.